Adia Med Inc.

Adia Med Inc.

ADIA
Adia Med Inc.US flagOther OTC
0.10
USD
-0.02
- -
9.51MMarket Cap
2024 Y
2025 Y
TTM
Revenue per Share
- -
0.01
0.01
Basic EPS, GAAP
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
Dividend per Share
- -
- -
- -
Book Value per Share
-0.17
-0.17
-0.17
Tangible Book Value per Share
- -
- -
- -
Basic Weighted Avg Shares
92
94
93
Sales/Revenue/Turnover
- -
1
1
Operating Margin (%)
-2,739.01
-52.32
-54.08
Depreciation Expense
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
Profit Margin (%)
-2,838.04
-56.45
-58.55
Working Capital
- -
- -
-1
LT Debt
1
1
- -
Total Equity
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
Return on Capital (%)
- -
- -
2.91
Return on Common Equity (%)
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
1
LT Borrowings
1
1
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
94
94
94
Market Capitalization
4
7
9

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
1
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-1,108.9%
Free Cash Flow
- -
- -
-46.76%
Net Income, GAAP
- -
- -
118.41%
Sales/Revenue/Turnover
- -
- -
10,879.75%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Larry Powalisz
Full Time Employees
3
Sector
Healthcare
Industry
Shell Companies
Address
PO Box 636 Winter Park FL United States of America 96760
IPO Date
Apr 11, 2012
Business
Adia Nutrition, Inc. (OTCQB: ADIA) develops and markets nutritional supplements and advanced medical treatments focused on regenerative healthcare and wellness. The company operates through a supplement division offering premium probiotic drink mixes including balanced berry, unsweetened green tea, raspberry lemonade slim, lemon lime sport, and orange mango flavors; probiotic chews in berry and lemonade varieties; and functional beverages such as Biolete protein coffee infused with adaptogens and mushrooms like Cordyceps, Reishi, Lion's Mane, Shiitake, and Turkey Tail for energy, focus, mood enhancement, muscle recovery, and anti-inflammatory benefits; and a medical division providing autologous hematopoietic stem cell transplantation (aHSCT) for multiple sclerosis, therapeutic plasma exchange (TPE), stem cell therapies, platelet-rich plasma (PRP) injections, orthopedic and pain management services, and wound repair through Adia Med clinics. Products are sold online, through nutrition stores, and via AdiaVita and AdiaLink branded HCT/Ps; services target consumers, healthcare providers, and patients with chronic conditions across the United States with nationwide clinic expansion. Founded in 1999 and headquartered in Winter Park, Florida, the company formerly known as PivX Solutions Inc. changed its name in May 2004. Recent developments include the acquisition of Biolete to enter the functional beverage market; a strategic partnership with Cement Factory Nutrition co-owned by former WWE wrestler Jeff Sciullo to diversify supplements; a $500,000 line of credit from CEO Larry Powalisz for aHSCT clinic growth; partnerships with Aetna (effective July 2025) and pending United Healthcare inclusion to access millions of insured patients for regenerative therapies; a request to update its SIC code to 2836 for biological products reflecting stem cell and biologic advancements; filing of a patent application for regenerative medicine protocols via AdiaLabs LLC; and rapid sales force tripling for U.S. and global expansion.

Company News

APIChatGPT
  • Adia Med Inc. (Formerly Adia Nutrition Inc.) Launches Redesigned Corporate Website

  • Adia Med's Rise, Highlighting 2.5 Years of Growth Toward NASDAQ

  • Adia Nutrition to Trade as Adia Med Inc. After Lightning-Fast FINRA Review

  • Adia Nutrition Inc. Enters FINRA Home Stretch for Corporate Name Change to Adia Med Inc.

  • Adia Med Finds Another Unicorn

  • Adia Med Improves Quality of Care with Advanced Ultrasound-Guided IV Training

  • Adia Nutrition Inc. Delivers Exciting Update: Name Change to Adia Med Inc. Now Official in Nevada

  • Adia Nutrition Launches Dynamic New Subsidiary ADIA Life LLC in Florida to Supercharge Distribution and Unlock a Full Spectrum of Life-Transforming Wellness Solutions

  • Adia Nutrition, Inc. Drops Explosive Sneak Peek of Upcoming Documentary Featuring TNA Wrestling Star Jeff Sciullo (Elias)

  • Adia Nutrition Announces Expanded Stem Cell Coverage Through Independent Monthly-Membership Health Care Sharing Ministry

  • Adia Med Now Recruiting for Kidney Health and Lower Back Pain Studies Listed on ClinicalTrials.gov

  • ADIA Nutrition, Inc. Reports Strong Revenue Growth and Operational Momentum for First Quarter 2026

  • ADIA Nutrition Announces IRB Approval of All Four Clinical Studies and Registration of Kidney Health Study on ClinicalTrials.gov

  • Adia Nutrition Announces IRB Approval and ClinicalTrials.gov Submission for Groundbreaking Stem Cell Study in Chronic Kidney Disease (CKD)

  • Adia Nutrition Announces Three Pivotal Clinical Studies Receive Major IRB Milestone - Final Approval Now Clearly in Sight

  • Adia Nutrition, Inc. Announces Corporate Name Change to Adia Med, Inc. to Better Align with Its Regenerative Medicine and Biologics Business Model

  • Adia Nutrition Strikes Major Partnership with Leading Atlanta Clinic to Launch Groundbreaking Autism Clinical Study

  • Adia Nutrition, Inc. Reports Strong Revenue Growth in 2025 Annual Report, Highlighting Transition to Regenerative Medicine and Full SEC Reporting Status

  • Tonight: Adia Nutrition and UCF CARD Host Live Zoom on Revolutionary Stem Cell Study for Autism - Strong Interest Already Building

  • Adia Med of Winter Park Appoints Amy Dalrymple, APRN, Former Mrs. Florida United States, to Lead Regenerative Aesthetics Division